Get started
Work

Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial

Year: 2017
Type: article
DOI: 10.1016/j.amjmed.2017.06.026
Authors: Chiara Melloni, Allison Dunning, Christopher B. Granger, Laine Thomas, Michel G. Khouri, David A. Garcia, Elaine M. Hylek, Michael Hanna, Lars Wallentin, Bernard J. Gersh, Pamela S. Douglas, John H. Alexander, Renato D. Lopes
Institutions: Duke University, Duke Medical Center, Duke Clinical Research Institute, University of Washington, Boston University, Bristol-Myers Squibb (United States), Uppsala University, Mayo Clinic
Language: English
Field: Medicine
Open Access status: bronze
Funders: Boehringer Ingelheim, Abbott Laboratories, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Sanofi, Medtronic, Gilead Sciences, Takeda Pharmaceuticals U.S.A., CSL Behring, Portola Pharmaceuticals, Medicines Company, Bayer Fund, Tenax Therapeutics, Daiichi-Sankyo, National Institutes of Health, U.S. Food and Drug Administration, GE Healthcare, Medtronic Foundation, Duke Clinical Research Institute, Janssen Pharmaceuticals
OpenAlex ID: W2737919013
FWCI: 11.18
Cites: 19
Cited by: 165
Related to: 10